Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Approved biosimilar ranibizumab—a global update

Eye volume 37, pages 200–202 (2023)Cite this article

Subjects

The innovator ranibizumab molecule’s (Lucentis, Genentech, USA) patent expired in June 2020 (USA) and July 2022 (EU) [1]. This has led to a flurry of new drug applications and approval of biosimilar ranibizumab across the globe. There are many biosimilar ranibizumab molecules that have already been approved worldwide. Some molecules are being marketed with different brand names in different regions. This manuscript will help update ophthalmologists about the approved biosimilar ranibizumab worldwide with data of the phase 3 results in brief (Table 1).

Table 1 Key characteristics of phase 3 clinical trial design.
Full size table

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna). 2022. https://investors.biogen.com/news-releases/news-release-details/fda-approves-samsung-bioepis-and-biogens-byooviztm-sb11.

  2. Ranibizumab Biosimilar (Byooviz) Gains EU Marketing Authorization. 2022. https://www.centerforbiosimilars.com/view/samsung-bioepis-byooviz-gains-ema-marketing-authorization.

  3. Woo SJ, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, et al. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2021;139:68–76.

    Article  Google Scholar 

  4. Bressler NM, Veith M, Hamouz J, Ernest J, Zalewski D, Studnicka J, et al. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. Br J Ophthalmol. 2021:bjophthalmol-2021-319637.

  5. European Commission approves FYB201/Ranivisio®1 (Ranivisio—Ranibizumab), a biosimilar to Lucentis. 2022. https://www.formycon.com/en/press-release/european-commission-approves-fyb201-ranivisio1-ranivisio-ranibizumab-a-biosimilar-to-lucentis2/.

  6. United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) grants Marketing Authorization for FYB201, Formycon’s Biosimilar for Lucentis®¹, to be Commercialized by Teva as ONGAVIA®. 2022. https://www.formycon.com/en/press-release/united-kingdom-medicines-and-healthcare-products-regulatory-agency-mhra-grants-marketing-authorization-for-fyb201-formycons-biosimilar-for-lucentis1-to-be-commercialized-by-teva-as-ongavia/.

  7. FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity. 2022. https://investors.coherus.com/news-releases/news-release-details/fda-approves-coherus-cimerlitm-ranibizumab-eqrn-first-and-only.

  8. Holz FG, Oleksy P, Ricci F, Kaiser PK, Kiefer J, Schmitz-Valckenberg S, et al. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2022;129:54–63.

    Article  Google Scholar 

  9. Ranibizumab similar biologic launched in India. 2022. https://www.gabionline.net/biosimilars/news/Ranibizumab-similar-biologic-launched-in-India.

  10. Apsangikar P, Ghadge P, Naik M, Nair S, Payghan R. Randomised, double-blind, comparative clinical study of new ranibizumab biosimilar in neovascular (wet) age-related macular degeneration. Clin Ophthalmol. 2021;15:3087–95.

    Article  Google Scholar 

  11. Singh R, Chauhan R, Saxena A, Shah A, Mondal L, Bakhle D, et al. A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration. Indian J Ophthalmol. 2022;70:3008–14.

    Article  Google Scholar 

Download references

Acknowledgements

We would like to acknowledge help from Ira Steinberg, Coherus Biosciences, CA, USA, Alok Rasal, Intas pharmaceuticals, Ahmedabad, India and Oriol Mora Maltas, Biogen International GmbH, Baar, Switzerland for their contribution in sharing inputs on phase 3 data results of their products. BDK acknowledges an unrestricted grant from Research to Prevent Blindness to the Gavin Herbert Eye Institute at the University of California, Irvine.

Author information

Authors and Affiliations

  1. Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, Tamil Nadu, India

    Ashish Sharma

  2. Department of Ophthalmology, Mie University Graduate School of Medicine, Tsu, Japan

    Mineo Kondo

  3. Department of Ophthalmology, Kindai University of Medicine, Osaka, Japan

    Chiharu Iwahashi

  4. Sankara Eye Hospital, Coimbatore, Tamil Nadu, India

    Nikulaa Parachuri

  5. Madhavi Netralaya, Ara, Bihar, India

    Nilesh Kumar

  6. University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy

    Francesco Bandello

  7. Division of Ophthalmology, Tel Aviv Medical, Tel Aviv University, Tel Aviv, Israel

    Anat Loewenstein

  8. Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA

    Baruch D. Kuppermann

Authors
  1. Ashish Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mineo Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chiharu Iwahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nikulaa Parachuri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nilesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Francesco Bandello
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anat Loewenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Baruch D. Kuppermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AS: conception, analysis, drafting, integrity check, final approval. MK, CI, NP, NK, FB, AL, and BDK: drafting, revision, analysis, integrity check.

Corresponding author

Correspondence to Ashish Sharma.

Ethics declarations

Competing interests

AS: Consultant: for Novartis, Allergan, Bayer and Intas. MK: Clinical Research: Alcon, Bayer, Hoya, Kowa, Novartis, Otsuka, Santen, Senju; Consultant: Chugai, Daicel, Novartis, Ono, Sanofi, Asahi-Kasei, Senju. CI: none. FB: Consultant: Allergan, Bayer, Boehringer Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. AL reports other from Allergan, other from Novartis, other from Roche, other from Notal Vision, other from Forsightslabs, other from Beyeonics, other from Bayer Health Care. BDK: Clinical Research: Alimera, Allegro, Allergan, Apellis, Boehringer Ingelheim, Clearside, Genentech, GSK, Ionis, IvericBio, jCyte, Novartis, Regeneron; Consultant: Alimera, Allegro, Allergan, Eyebio, Eyedaptic, Galimedix, Genentech, Glaukos, Interface Biologics/Ripple Therapeutics, IvericBio, jCyte, Novartis, Regeneron, Revana, Theravance Biopharma. NK: none. NP: none.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Kondo, M., Iwahashi, C. et al. Approved biosimilar ranibizumab—a global update. Eye 37, 200–202 (2023). https://doi.org/10.1038/s41433-022-02246-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41433-022-02246-5

Search

Advanced search

Quick links